Aromatase

Metalloestrogens#

Cadmium and Nickel are classified as metalloestrogens—metals that mimic estrogen by binding estrogen receptors (ERα) and activating estrogen-responsive gene transcription WITHOUT going through aromatase.^{[1]Role of Cadmium and Nickel in Estrogen Receptor Signaling and Breast Cancer: Metalloestrogens or Not?Aquino NB, Sevigny MB, Sabangan J et al. · 2012Open reference 1 ↓} This creates a paradox for aromatase inhibitor therapy.

Aromatase inhibitors (letrozole, anastrozole) block enzymatic estrogen production but cannot block metalloestrogen activation of ER. Environmental cadmium/nickel exposure may therefore undermine aromatase inhibitor efficacy in breast cancer and endometriosis.

Estrobolome Circuit#

Aromatase produces estrogen → estrogen is conjugated in the liver → conjugated estrogen enters the gut via bile → gut bacterial Beta-Glucuronidase deconjugates it → free estrogen is reabsorbed (Estrobolome recirculation). Dysbiosis alters the estrobolome, disrupting this circuit.

Increased beta-glucuronidase activity → more estrogen recirculation → estrogen excess → endometriosis/breast cancer risk.^{[3]Kaliannan et al. 2018 — Estrogen-Mediated Gut Microbiome Alterations Influence Sexual Dimorphism in Metabolic Syndrome in MiceKanakaraju Kaliannan, Ruairi C. Robertson, Kiera Murphy et al. · 2018Open reference 3 ↓} Decreased beta-glucuronidase activity → less recirculation → estrogen depletion → metabolic syndrome, osteoporosis risk.

Aromatase and the estrobolome are two halves of estrogen homeostasis—one controls production, the other controls recycling. Both must be intact for normal estrogen levels.

Adipose Aromatase and Obesity-Microbiome Axis#

In obesity, adipose tissue becomes a major estrogen source via aromatase expression. The Gut Microbiome drives obesity-related inflammation → adipose expansion → increased aromatase → peripheral estrogen production. This explains.

Sex differences in CRC: Higher estrogen from adipose aromatase in obese men may be protective or pathogenic depending on context.^{[4]Sex differences in colorectal cancer: with a focus on sex hormone-gut microbiome axisZihong Wu, Yuqing Huang, Renyi Zhang et al. · 2024Open reference 4 ↓}

Postmenopausal breast cancer: Adipose aromatase becomes the primary estrogen source after ovarian cessation; obesity-driven microbiome inflammation amplifies this.

Breast Cancer#

Aromatase inhibitors are first-line therapy for ER+ postmenopausal breast cancer. The microbiome modulates treatment response through. Estrobolome activity affecting circulating estrogen levels despite aromatase blockade.

Metalloestrogen exposure bypassing aromatase inhibition entirely.